Tetraneuron presented an AAV‑based gene therapy approach, TET‑101, that targets the transcription factor E2F4 to prevent aberrant neuronal cell‑cycle reentry—an upstream mechanism the company argues contributes to Alzheimer’s pathology. Company leadership described preclinical work and a rationale for addressing multiple downstream drivers of neurodegeneration by intervening earlier in the molecular cascade. The therapy aims to modulate fundamental neuronal survival pathways rather than directly targeting amyloid or tau aggregates; Tetraneuron traces its program to academic discoveries from José Frade’s lab and is positioning the approach as complementary to other modalities in development.